The data show 100% protection against severe disease, hospitalisation and death, greater vaccine efficacy with an inter-dose interval of 12 weeks or more, and the potential for reduced asymptomatic transmission
Read More
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read More
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
Read More
The move follows a green light by the UK’s MHRA
Read More
Data will be reviewed after a study volunteer experienced an unexpected illness
Read More
Clinical development of AZD1222 is progressing globally with late-stage clinical trials ongoing in the UK, Brazil and South Africa
Read More
New initiatives will raise public awareness of the burden of heart failure to boost prevention, diagnosis and treatment
Read More
AZ says approval would “simplify and improve treatment by enabling continuity of care while minimising the risk of exposure to infection in the healthcare setting”
Read More
High SABA inhaler use was associated with around twice the number of exacerbations, the SABINA study found
Read More
Up to 400 million doses of AZD1222 will be supplied to EU member states under the deal
Read More
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
Read More
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Read More
